Jefferies Downgrades uniQure BV (QURE) to Hold

November 22, 2016 9:46 AM EST
Get Alerts QURE Hot Sheet
Price: $5.88 -1.67%

Rating Summary:
    10 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 9
Trade QURE Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Jefferies downgraded uniQure BV (NASDAQ: QURE) from Buy to Hold with a price target of $8.00 (from $28.00) on execution risk and lack of major near-term catalysts.

Analyst Eun Yang commented, "Once viewed as the most advanced gene therapy platform company (& landmark gene therapy deal w/ BMY in 2015), today QURE's position is overshadowed by lack of progress, competition & poor execution. Its strategic review & prioritization announced last wk comes up short in providing confidence in strategy/execution. In addition, with no apparent NT key catalysts, we move to Hold until we see a turnaround in execution."

For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.

Shares of uniQure BV closed at $7.13 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Downgrades

Related Entities

Jefferies & Co

Add Your Comment